Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 3 | 2022 | 2903 | 0.810 |
Why?
|
| Trastuzumab | 1 | 2019 | 68 | 0.680 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 223 | 0.650 |
Why?
|
| Paclitaxel | 1 | 2019 | 460 | 0.600 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2016 | 18 | 0.580 |
Why?
|
| Naphthalenes | 1 | 2016 | 45 | 0.570 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 455 | 0.570 |
Why?
|
| Imidazoles | 1 | 2016 | 162 | 0.540 |
Why?
|
| Lymph Nodes | 1 | 2019 | 533 | 0.530 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 113 | 0.530 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 137 | 0.470 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2011 | 35 | 0.430 |
Why?
|
| Burkitt Lymphoma | 1 | 2012 | 31 | 0.430 |
Why?
|
| Boronic Acids | 1 | 2012 | 55 | 0.430 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 43 | 0.430 |
Why?
|
| Pyrazines | 1 | 2012 | 92 | 0.410 |
Why?
|
| Stomach Neoplasms | 3 | 2020 | 266 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 151 | 0.380 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 61 | 0.370 |
Why?
|
| Meningioma | 1 | 2010 | 59 | 0.370 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2010 | 9 | 0.360 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 105 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 589 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 645 | 0.340 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 162 | 0.330 |
Why?
|
| Transcriptome | 1 | 2012 | 580 | 0.310 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 736 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 2438 | 0.240 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7998 | 0.230 |
Why?
|
| Female | 12 | 2022 | 44547 | 0.230 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6513 | 0.220 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1938 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.210 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.210 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 1169 | 0.210 |
Why?
|
| Risk Reduction Behavior | 1 | 2022 | 98 | 0.200 |
Why?
|
| Tamoxifen | 1 | 2022 | 168 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 322 | 0.190 |
Why?
|
| Aged | 9 | 2020 | 18421 | 0.190 |
Why?
|
| Mastectomy | 1 | 2022 | 243 | 0.180 |
Why?
|
| Humans | 15 | 2022 | 86656 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 184 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Adult | 6 | 2022 | 25657 | 0.160 |
Why?
|
| Stroke Volume | 2 | 2011 | 456 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 468 | 0.150 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 18 | 0.140 |
Why?
|
| Postmenopause | 1 | 2016 | 98 | 0.140 |
Why?
|
| Hormones | 1 | 2016 | 141 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 30 | 0.140 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 167 | 0.140 |
Why?
|
| Middle Aged | 7 | 2020 | 25036 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 384 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 318 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 28 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 134 | 0.110 |
Why?
|
| Genes, myc | 1 | 2012 | 39 | 0.110 |
Why?
|
| Young Adult | 2 | 2022 | 5980 | 0.110 |
Why?
|
| Bortezomib | 1 | 2012 | 76 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 154 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 114 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 295 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 265 | 0.100 |
Why?
|
| Hyperamylasemia | 1 | 2011 | 2 | 0.100 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2011 | 14 | 0.100 |
Why?
|
| Osteoclasts | 1 | 2011 | 33 | 0.100 |
Why?
|
| Heart Arrest, Induced | 1 | 2011 | 31 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2011 | 478 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1197 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2011 | 87 | 0.090 |
Why?
|
| Male | 9 | 2020 | 40984 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 252 | 0.090 |
Why?
|
| Prognosis | 1 | 2016 | 3680 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 318 | 0.080 |
Why?
|
| Survival Rate | 1 | 2010 | 1864 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 916 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 3243 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2011 | 4215 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 2898 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1961 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 3642 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 5211 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1721 | 0.050 |
Why?
|
| Leucovorin | 1 | 2020 | 218 | 0.040 |
Why?
|
| Dideoxynucleosides | 1 | 2018 | 2 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 556 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 86 | 0.040 |
Why?
|
| United States | 1 | 2010 | 6680 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 180 | 0.040 |
Why?
|
| Animals | 1 | 2016 | 26590 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 26 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 334 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 270 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Quinazolines | 1 | 2016 | 220 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2011 | 6 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 72 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 42 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2011 | 62 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 129 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 303 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 1204 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1139 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1464 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 592 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1564 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 1719 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3361 | 0.010 |
Why?
|